FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000520929> ?p ?o ?g. }

• W2000520929 endingPage "57" @default.
• W2000520929 startingPage "50" @default.
• W2000520929 abstract "Objective Meropenem is a broad-spectrum antibiotic used for severe infections. In patients with chronic end-stage renal failure, meropenem clearance is reduced and doses must be adjusted according to the creatinine clearance. The aim of this study was to assess pharmacokinetic data of meropenem in patients with acute renal failure and to determine the amount of drug removed by continuous venovenous hemofiltration, an often-used renal replacement therapy in patients with acute renal failure. Methods Nine critically ill anuric patients with acute renal failure undergoing continuous venovenous hemofiltration received 500 mg meropenem 2 or 3 times daily. Plasma and hemofiltrate concentrations were determined during 1 dosing interval at steady state. Pharmacokinetic parameters were calculated for a 2-compartment open model and dose requirements were calculated. Results The total meropenem clearance was 52.0 ± 8.4 mL/min, with a hemofiltration clearance of 22.0 ± 4.7 mL/min and a nonrenal-nonhemofiltration clearance of 29.9 ± 5.4 mL/min; 235.9 ± 88.6 mg, or 47.2% ± 17.7%, of the dose were removed through continuous venovenous hemofiltration. The terminal elimination half-life was 8.7 ± 3.5 hours and the volume of distribution at steady state was 12.4 ± 1.8 L. Peak and trough concentrations for a dosing interval of 12 hours were 38.9 ± 9.7 mg/L and 7.3 ± 1.3 mg/L, respectively. The corresponding concentrations for a dosing interval of 8 hours were 44.7 ± 10.4 mg/L and 11.9 ± 0.7 mg/L, respectively. Conclusion Pharmacokinetic data of anuric patients with acute renal failure were similar to those of patients with end-stage renal failure. Because hemofiltration contributes significantly to meropenem elimination, the recommended dose for critically ill anuric patients receiving continuous venovenous hemofiltration should be increased by 100% to avoid potential underdosing. Clinical Pharmacology & Therapeutics (1999) 65, 50–57; doi:" @default.
• W2000520929 created "2016-06-24" @default.
• W2000520929 creator A5017400006 @default.
• W2000520929 creator A5020387821 @default.
• W2000520929 creator A5027292872 @default.
• W2000520929 creator A5061189766 @default.
• W2000520929 creator A5072053002 @default.
• W2000520929 creator A5078612562 @default.
• W2000520929 date "1999-01-01" @default.
• W2000520929 modified "2023-09-25" @default.
• W2000520929 title "Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration" @default.
• W2000520929 cites W1972480385 @default.
• W2000520929 cites W1972773258 @default.
• W2000520929 cites W1974666259 @default.
• W2000520929 cites W1977992908 @default.
• W2000520929 cites W1981341506 @default.
• W2000520929 cites W1983668880 @default.
• W2000520929 cites W1989868875 @default.
• W2000520929 cites W2016290349 @default.
• W2000520929 cites W2019411066 @default.
• W2000520929 cites W2021712825 @default.
• W2000520929 cites W2026377015 @default.
• W2000520929 cites W2031681859 @default.
• W2000520929 cites W2033990028 @default.
• W2000520929 cites W2036487127 @default.
• W2000520929 cites W2045658905 @default.
• W2000520929 cites W2050190937 @default.
• W2000520929 cites W2054319595 @default.
• W2000520929 cites W2056398093 @default.
• W2000520929 cites W2058536855 @default.
• W2000520929 cites W2064318272 @default.
• W2000520929 cites W2065724991 @default.
• W2000520929 cites W2074743637 @default.
• W2000520929 cites W2079867796 @default.
• W2000520929 cites W2092448032 @default.
• W2000520929 cites W2092829687 @default.
• W2000520929 cites W2097171403 @default.
• W2000520929 cites W2098798296 @default.
• W2000520929 cites W2101215665 @default.
• W2000520929 cites W2111092491 @default.
• W2000520929 cites W2111547348 @default.
• W2000520929 cites W2113605290 @default.
• W2000520929 cites W2114368944 @default.
• W2000520929 cites W2115119443 @default.
• W2000520929 cites W2125142536 @default.
• W2000520929 cites W2128253624 @default.
• W2000520929 cites W2145758319 @default.
• W2000520929 cites W2148375190 @default.
• W2000520929 cites W2157047056 @default.
• W2000520929 cites W2169794607 @default.
• W2000520929 cites W2461960389 @default.
• W2000520929 doi "https://doi.org/10.1016/s0009-9236(99)70121-9" @default.
• W2000520929 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9951430" @default.
• W2000520929 hasPublicationYear "1999" @default.
• W2000520929 type Work @default.
• W2000520929 sameAs 2000520929 @default.
• W2000520929 citedByCount "73" @default.
• W2000520929 countsByYear W20005209292012 @default.
• W2000520929 countsByYear W20005209292013 @default.
• W2000520929 countsByYear W20005209292014 @default.
• W2000520929 countsByYear W20005209292015 @default.
• W2000520929 countsByYear W20005209292016 @default.
• W2000520929 countsByYear W20005209292017 @default.
• W2000520929 countsByYear W20005209292018 @default.
• W2000520929 countsByYear W20005209292019 @default.
• W2000520929 countsByYear W20005209292020 @default.
• W2000520929 countsByYear W20005209292021 @default.
• W2000520929 countsByYear W20005209292022 @default.
• W2000520929 countsByYear W20005209292023 @default.
• W2000520929 crossrefType "journal-article" @default.
• W2000520929 hasAuthorship W2000520929A5017400006 @default.
• W2000520929 hasAuthorship W2000520929A5020387821 @default.
• W2000520929 hasAuthorship W2000520929A5027292872 @default.
• W2000520929 hasAuthorship W2000520929A5061189766 @default.
• W2000520929 hasAuthorship W2000520929A5072053002 @default.
• W2000520929 hasAuthorship W2000520929A5078612562 @default.
• W2000520929 hasConcept C112705442 @default.
• W2000520929 hasConcept C126322002 @default.
• W2000520929 hasConcept C126894567 @default.
• W2000520929 hasConcept C139254425 @default.
• W2000520929 hasConcept C159641895 @default.
• W2000520929 hasConcept C185592680 @default.
• W2000520929 hasConcept C2777288759 @default.
• W2000520929 hasConcept C2778063415 @default.
• W2000520929 hasConcept C2778865887 @default.
• W2000520929 hasConcept C2779375183 @default.
• W2000520929 hasConcept C2779541074 @default.
• W2000520929 hasConcept C2780472472 @default.
• W2000520929 hasConcept C42219234 @default.
• W2000520929 hasConcept C501593827 @default.
• W2000520929 hasConcept C55493867 @default.
• W2000520929 hasConcept C71924100 @default.
• W2000520929 hasConcept C94665300 @default.
• W2000520929 hasConcept C98274493 @default.
• W2000520929 hasConceptScore W2000520929C112705442 @default.
• W2000520929 hasConceptScore W2000520929C126322002 @default.
• W2000520929 hasConceptScore W2000520929C126894567 @default.
• W2000520929 hasConceptScore W2000520929C139254425 @default.

• next